February 2025 – Page 6 – Talk Bio

Actionable Insights Powered by AI

EU PFAS Ban Threatens Pharmaceutical Packaging Industry: Challenges and Implications

2 months ago talkbio0Tagged chain disruption, chemical alternatives, drug safety, environmental, EU, PFAS gene, Pharmaceutical Packaging, regulatory

PFAS ban, pharmaceutical packaging, EU regulations, supply chain disruption, chemical alternatives, environmental protection, drug safety

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Supernus Pharmaceuticals’ Depression Drug SPN-820 Fails to Meet Primary Endpoint in Phase 2b Trial

2 months ago talkbio0Tagged Clinical Research, Effect, Failure (biologic function), MADRS score, Placebos, SPN-820, Supernus Pharmaceuticals, treatment-resistant depression

Supernus Pharmaceuticals, SPN-820, treatment-resistant depression, Phase 2b trial, clinical study failure, MADRS score, placebo effect

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

2 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens

2 months ago talkbio0Tagged Cryptigen, CryptoMap platform, DNA, Epitopea, heroin, Immunotherapy, Immunotherapy for cancer, Merck & Co., tumor-specific antigens

Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies

Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data

2 months ago talkbio0Tagged ASC30, Ascletis, Chinese Language, Glucagon-Like Peptide 1, Obesity, Oral cavity, Pharma, pharmaceutical innovation

Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation

Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases

2 months ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, CABA-201, CAR-T, Clinical Trials, Lupus Vulgaris

CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion

Siemens Healthineers Expands U.S. Supply Chain with Strategic ‘Mega Depots’ to Combat Logistics Challenges

2 months ago talkbio0Tagged Equipment and supply inventories, expansion, GXO, Health care facility, Logistics, mega depots, Partnership, Siemens Healthineers

Siemens Healthineers, supply chain resilience, mega depots, logistics expansion, healthcare equipment, parts inventory, GXO partnership

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

2 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Legal Challenges Mount Against Trump’s NIH Funding Cuts

2 months ago talkbio0Tagged Economics, Impact food supplement, Indirect, NIH Mouse, research universities, Transitory

NIH funding cuts, indirect costs, research universities, lawsuits, temporary restraining order, economic impact